Sanket Borgaonkar, MD
Interventional Cardiology · Houston, TXNPI 1720408032
Payments from drug & device makers
Across 647 payments — averaging $42.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$16K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- Amgen$1K
- Medtronic$1K
- E.r. Squibb & Sons, L.L.C.$648
- plus $5K from 29 others
What the payments were for
- Travel & lodging$3,17811%
- Food & beverage$24,39688%
- Education$1360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 298 | $16,412 |
| Boston Scientific | 48 | $1,754 |
| Edwards Lifesciences | 12 | $1,494 |
| Amgen | 61 | $1,242 |
| Medtronic(2 entities) | 20 | $1,037 |
| E.r. Squibb & Sons, L.L.C. | 36 | $648 |
| Novo Nordisk | 9 | $645 |
| Pfizer | 40 | $635 |
| Novartis | 21 | $467 |
| AstraZeneca | 10 | $439 |
| Biotronik Inc. | 7 | $433 |
| Abiomed | 3 | $428 |
| Johnson & Johnson | 15 | $353 |
| GE HealthCare | 4 | $315 |
| Tactile Systems Technology Inc | 13 | $252 |
| Regeneron Healthcare Solutions, Inc. | 5 | $141 |
| Merck | 7 | $139 |
| Esperion Therapeutics, Inc. | 8 | $137 |
| Cardiovascular Systems Inc. | 2 | $121 |
| Boehringer Ingelheim | 6 | $114 |
| Bridgebio Pharma, Inc. | 3 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $60 |
| Kestra Medical Technology Services, Inc. | 2 | $45 |
| Shockwave Medical, Inc | 1 | $42 |
| Biosense Webster, Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Bayer | 1 | $26 |
| Cvrx, Inc. | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Osprey Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$2,547
- CardioMEMS HF System$1,960
- CARDIOMEMS$1,576
- Quadra Assura CRT Defibrillator$779
- Impella$428
- Repatha$374
- GALLANT$364
- QUADRA ASSURA$348
- SAPIEN 3 Ultra RESILIA$283
- Allure Quadra RF CRT Pacemaker$263
- Assurity Pacemaker$257
- FARXIGA$228
- SYNERGY$215
- Epic$204
- Fortify Assura, Ellipse ICD$174
- Confirm Rx$151
- ONYX FRONTIER$149
- ALLIA$148
- Fortify Assura$143
- Merlin Connectivity and Remote$143
How this compares
$27,709 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $86,848 |
| Repatha SureclickEvolocumab | 34 | $33,600 |
| XareltoRivaroxaban | 30 | $31,370 |
| JardianceEmpagliflozin | 21 | $22,060 |
| EntrestoSacubitril/Valsartan | 21 | $17,684 |
| BrilintaTicagrelor | 12 | $15,034 |
| FarxigaDapagliflozin Propanediol | 21 | $13,119 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $7,177 |
| Nifedipine ErNifedipine | 64 | $2,044 |
| ClopidogrelClopidogrel Bisulfate | 104 | $1,034 |
| Metoprolol Succinate | 108 | $959 |
| Losartan Potassium | 130 | $956 |
| Rosuvastatin Calcium | 97 | $936 |
| Ranolazine ErRanolazine | 12 | $902 |
| Atorvastatin Calcium | 73 | $896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $635 | $86,848118 claims |
| Johnson & JohnsonXarelto | $353 | $31,37030 claims |
| AstraZenecaBrilinta, Farxiga | $439 | $28,15233 claims |
| Boehringer IngelheimJardiance | $114 | $22,06021 claims |
| NovartisEntresto | $467 | $17,68421 claims |
| Esperion Therapeutics, Inc.Nexlizet | $137 | $7,17713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.